• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Clearside Biomedical prices $36m IPO

December 9, 2016 By Sarah Faulkner

Clearside prices $36m IPOClearside Biomedical (NSDQ:CLSD) today priced its $36 million initial public offering, floating 4 million shares at $9 apiece and including a 30-day underwriters option for 600,000 more shares.

Alpharetta, Ga.-based Clearside said it plans to use theIPO proceeds to fund a pivotal Phase III trial of its suspension formulation of corticosteroid triamcinolone acetonide, Zuprata, for the treatment of macular edema associated with non-infectious uveitis. It will also launch a Phase III clinical program of suprachoroidal Zuprata with Eylea, an intravitreal anti-VEGF agent, to treat macular edema associated with retinal vein occlusion.

The company is also planning to use the cash to complete a Phase I/II study of Zuprata as a monotherapy and Eylea as a treatment for diabetic macular edema, as well as launch and complete a Phase I/II trial of axitinib for wet age-related macular degeneration.

Last month, Clearside launched a Phase I/II trial evaluating Zuprata as a treatment for diabetic macular edema. The trial is slated to enroll 20 patients, with equal participation in both treatment arms. One group will receive Zuprata administered in the suprachoroidal space along with intravitreal aflibercept; the 2nd group will receive Zuprata as an independent therapy.

Clearside posted its 3rd-quarter results last month, topping expectations on Wall Street, and named Rick McElheny as VP of business development.

Filed Under: Featured, Initial Public Offering (IPO), Optical/Ophthalmic, Wall Street Beat Tagged With: Clearside Biomedical

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS